Status:
COMPLETED
PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in Frontotemporal Dementia
Lead Sponsor:
National Institute of Mental Health (NIMH)
Conditions:
Frontotemporal Lobar Degeneration
Dementia
Eligibility:
All Genders
35+ years
Brief Summary
This study will use positron emission tomography (PET) imaging to measure a receptor in the brain that is involved in inflammation. Certain neurological disorders, possibly including frontotemporal de...
Detailed Description
Objective: Abnormal immune responses and inflammatory mechanisms have been implicated in the pathogenesis of certain neurodegenerative diseases. Frontotemporal dementia (FTD) is a neurodegenerative d...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Patients with a diagnosis of Alzheimer disease or frontotemporal dementia (FTD). FTD patients with or without motor involvement may be included. FTD patients with either the frontal variant (also known as the behavioral variant) or the language variant of FTD may be included. AD and FTD patients must either meet capacity criteria to consent to research, or be able to assign a surrogate decision-maker who is able to consent to research on the subject s behalf.
- TLE patients must have clinically documented partial seizures with consistent EEG evidence as defined by the 1981 International Classification of Epileptic Seizures, refractory to standard antiepileptic treatment for at least one year. This criterion will be established by preliminary screening in the NINDS Clinical Epilepsy Section outpatient clinic, and if necessary, inpatient video-EEG monitoring.
- Healthy volunteers.
- EXCLUSION CRITERIA:
- Current psychiatric disease, substance abuse or severe systemic disease based on history and physical exam.
- Laboratory tests with clinically significant abnormalities.
- Prior participation in other research protocols or clinical care in the last year such that radiation exposure, including that from this protocol, would exceed the guidelines set by the Radiation Safety Committee (RSC).
- Pregnancy or breast feeding.
- Positive result on urine screen for illicit drugs.
- Subjects who cannot lie on their back for extended periods of time.
- History of neurological disease other than FTD or AD or TLE.
- TLE patients:
- with a known treatable seizure etiology such as neoplastic or infectious disease
- with an MRI finding consistent with a brain tumor, trauma or arterial-venous malformations
- with seizure activity within 24 hours prior to the study.
- not capable of giving an informed consent.
- Presence of ferromagnetic metal in the body or heart pacemaker.
Exclusion
Key Trial Info
Start Date :
January 31 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 13 2017
Estimated Enrollment :
108 Patients enrolled
Trial Details
Trial ID
NCT00613119
Start Date
January 31 2008
End Date
July 13 2017
Last Update
December 16 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892